Reduced postprandial proinsulinaemia and 32-33 split proinsulinaemia after a mixed meal in type 2 diabetic patients following sensitization to insulin with pioglitazone

Clinical Endocrinology

Volumn 68, Issue 5, 2008, Pages 738-746

  Cooper, Michael B ^a,b   Al Majali, Khulood ^b   Bailey, Clifford J ^c   Betteridge, D John ^b  

^a UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c ASTON UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; HEMOGLOBIN A1C; INSULIN; PIOGLITAZONE; PROINSULIN;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC PATIENT; DOUBLE BLIND PROCEDURE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RELEASE; INSULIN SENSITIVITY; INSULINEMIA; MALE; MEAL; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; POSTPRANDIAL STATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SENSITIZATION; TREATMENT RESPONSE;

ADULT; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; GLYBURIDE; HUMANS; HYPERINSULINISM; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; PROINSULIN; THIAZOLIDINEDIONES;

EID: 42149104644     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2007.03113.x     Document Type: Article

References (39)

1. Al Majali, K., Cooper, M.B., Staels, B., Luc, G., Taskinen, M.R. Betteridge, D.J. (2006) The effect of sensitisation to insulin with pioglitazone on fasting and postprandial lipid metabolism lipoprotein modification by lipases and lipid transfer activities in type 2 diabetic patients. Diabetologia, 49, 527 537.
2. Tan, K.C., Cooper, M.B., Ling, K.L., Griffin, B.A., Freeman, D.J., Packard, C.J., Shepherd, J., Hales, C.N. Betteridge, D.J. (1995) Fasting and postprandial determinants for the occurrence of small dense LDL species in non-insulin-dependent diabetic patients with and without hypertriglyceridaemia: the involvement of insulin precursor species and insulin resistance. Atherosclerosis, 113, 273 287.
3. Seaquist, E.R., Kahn, S.E., Clark, P.M., Hales, C.N., Porte, D. Jr. & Robertson, R.P. (1996) Hyperproinsulinemia is associated with increased beta cell demand after hemipancreatectomy in humans. Journal of Clinical Investigation, 97, 455 460.
4. Bertuzzi, F., Saccomanno, K., Socci, C., Davalli, A.M., Taglietti, M.V., Berra, C., Dalcin, E., Monti, L.D., Pozza, G. Pontiroli, A.E. (1998) Long-term in vitro exposure to high glucose increases proinsulin-like-molecules release by isolated human islets. Journal of Endocrinology, 158, 205 211.
5. Furukawa, H., Carroll, R.J., Swift, H.H. Steiner, D.F. (1999) Long-term elevation of free fatty acids leads to delayed processing of proinsulin and prohormone convertases 2 and 3 in the pancreatic beta-cell line MIN6. Diabetes, 48, 1395 1401.
6. Yaney, G.C. Corkey, B.E. (2003) Fatty acid metabolism and insulin secretion in pancreatic beta cells. Diabetologia, 46, 1297 1312.
7. Prentki, M., Joly, E., El-Assaad, W. Roduit, R. (2002) Malonyl-CoA signaling lipid partitioning and glucolipotoxicity: role in beta-cell adaptation and failure in the etiology of diabetes. Diabetes, 51, S405 S413.
8. Zethelius, B., Byberg, L., Hales, C.N., Lithell, H. Berne, C. (2002) Proinsulin is an independent predictor of coronary heart disease: report from a 27-year follow-up study. Circulation, 105, 2153 2158.
9. Yudkin, J.S., May, M., Elwood, P., Yarnell, J.W., Greenwood, R. Davey-Smith, G. (2002) Concentrations of proinsulin-like molecules predict coronary heart disease risk independently of insulin: prospective data from the Caerphilly Study. Diabetologia, 45, 327 336.
10. Haffner, S.M. Hanley, A.J. (2002) Do increased proinsulin concentrations explain the excess risk of coronary heart disease in diabetic and prediabetic subjects? Circulation, 105, 2008.
11. Snehalatha, C., Ramachandran, A., Saltyamurthy, I., Satyavani, K., Sivasankari, S., Misra, J. Viswanathan, V. (2001) Association of proinsulin and insulin resistance with coronary artery disease in non-diabetic South Indian men. Diabetic Medicine, 18, 706 708.
12. Festa, A., D'Agostino, R. Jr., Mykkänen, L., Tracy, R.P., Zaccaro, D.J., Hales, C.N. Haffner, S.M. (1999) Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance. The Insulin Resistance Atherosclerosis Study (IRAS). Arteriosclerosis, Thrombosis, and Vascular Biology, 19, 562 568.
13. Nordt, T.K., Sawa, H., Fujii, S. Sobel, B.E. (1995) Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo. Circulation, 91, 764 770.
14. Cooper, M.B., Tan, K.C., Hales. C.N. Betteridge, D.J. (1996) Postprandial lipid metabolism and beta-cell function in non-insulin-dependent (type 2) diabetes mellitus after a mixed meal with a high fat content. Diabetic Medicine, 13, 816 827.
15. Semple, R.K., Chatterjee, V.K. O'Rahilly, S. (2006) PPAR gamma and human metabolic disease. Journal of Clinical Investigation, 116, 581 589.
16. Hevener, A.L., He, W., Barak, Y., Le, J., Bandyopadhyay1, G., Olson, P., Wilkes, J., Evans, R.M. Olefsky, J. (2003) Muscle-specific Pparg deletion causes insulin resistance. Nature Medicine, 9, 1491 1497.
17. Kim, H.I. Ahn, Y.H. (2004) Role of peroxisome proliferator-activated receptor-gamma in the glucose-sensing apparatus of liver and beta-cells. Diabetes, 53, S60 S65.
18. Ovalle, F. Bell, D.S. (2002) Clinical evidence of thiazolidinedione- induced improvement of pancreatic beta-cell function in patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism, 4, 56 59.
19. Smith, S.A., Porter, L.E., Biswas, N. Freed, M.I. (2004) Rosiglitazone but not glyburide reduces circulating proinsulin and the proinsulin: insulin ratio in type 2 diabetes. Journal of Clinical Endocrinology and Metabolism, 89, 6048 6053.
20. Kubo, K. (2002) Effect of pioglitazone on blood proinsulin levels in patients with type 2 diabetes. Endocrine Journal, 49, 323 328.
21. Fischer, S., Patzak, A., Rietzsch, H., Schwanebeck, U., Köhler, C., Wildbrett, J., Fuecker, K., Temelkova-Kurktschiev, T. Hanefeld, M. (2003) Influence of treatment with acarbose or glibenclamide on insulin sensitivity in type 2 diabetic patients. Diabetes, Obesity and Metabolism, 5, 38 44.
22. Sobey, W.J., Beer, S.F., Carrington, C.A., Clark, P.M., Frank, B.H., Gray, I.P., Luzio, S.D., Owens, D.R., Schneider, A.E., Siddle, K., Temple, R.C. Hales, C.N. (1989) Sensitive and specific two-site immunoradiometric assays for human insulin, proinsulin, 65-66 split and 32-33 split proinsulins. Biochemical Journal, 260, 535 540.
23. Matthews, D.R., Hosker, J.P., Rudenski, A.S., Naylor, B.A., Treacher, D.F. Turner, R.C. (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 28, 412 419.
24. Langenfeld, M.R., Forst, T., Hohberg, C., Kann, P., Lübben, G., Konrad, T., Füllert, S.D., Sachara, C. Pfützner, A. (2005) Pioglitazone decreases carotid intima-media thickness independently of glycaemic control in patients with type 2 diabetes mellitus. Circulation, 111, 2525 2531.
25. Haffner, S.M., D'Agostino, R., Mykkänen, L., Hales, C.N., Savage, P.J., Bergman, R.N., O'Leary, D., Rewers, M., Selby, J., Tracy, R. Saad, M.F. (1998) Proinsulin and insulin concentrations in relation to carotid wall thickness: Insulin Resistance Atherosclerosis Study. Stroke, 29, 1498 1503.
26. Båvenholm, P., Proudler, A., Tornvall, P., Godsland, I., Landou, C., de Faire, U. Hamsten, A. (1995) Insulin, intact and split proinsulin, and coronary artery disease in young men. Circulation, 92, 1422 1429.
27. Beysen, C., Karpe, F., Fielding, B.A., Clark, A., Levy, J.C. Frayn, K.N. (2002) Interaction between specific fatty acids, GLP-1 and insulin secretion in humans. Diabetologia, 45, 1533 1541.
28. De-Leon, D.D., Crutchlow, M.F., Ham, J.Y. Stoffers, D.A. (2006) Role of glucagon-like peptide-1 in the pathogenesis and treatment of diabetes mellitus. International Journal of Biochemistry and Cell Biology, 38, 845 859.
29. Bajaj, M., Suraamornkul, S., Pratipanawatr, T., Hardies, L., Pratipanawatr, W., Glass, L., Cersosimo, E., Miyazaki, Y. DeFronzo, R.A. (2003) Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes, 52, 1364 1370.
30. Ferrannini, E. Cobelli, C. (1987) The kinetics of insulin in man. II. Role of the liver. Diabetes/Metabolism Reviews, 3, 365 397.
31. Stumvoll, M., Fritsche, A., Stefan, N., Hardt, E. Haring, H. (2001) Evidence against a rate-limiting role of proinsulin processing for maximal insulin secretion in subjects with impaired glucose tolerance and beta-cell dysfunction. Journal of Clinical Endocrinology and Metabolism, 86, 1235 1239.
32. Leibowitz, G., Weintrob, N., Pikarsky, A., Josefsberg, Z., Landau, H., Glaser, B., Hales, C.N. Cerasi, E. (1996) Normal proinsulin processing despite beta-cell dysfunction in persistent hyperinsulinaemic hypoglycaemia of infancy (nesidioblastosis). Diabetologia, 39, 1338 1344.
33. Revers, R.R., Henry, R., Schmeiser, L., Schmeiser, O., Koltermann, R., Cohen, R., Polonsky, K., Jaspan, J., Rubenstein, A.H., Frank, B., Galloway, J. Olefsky, J.M. (1984) The effects of biosynthetic human proinsulin on carbohydrate metabolism. Diabetes, 33, 762 770.
34. Faber, O.K., Hagen, C., Binder, C., Markussen, J., Naithani, V.K., Blix, P.M., Kuzuya, H., Horwitz, D.L., Rubenstein, A.H. Rossing, N. (1978) Kinetics of human connecting peptide in normal and diabetic subjects. Journal of Clinical Investigation, 62, 197 203.
35. Horwitz, D.L., Starr, J.I., Mako, M.E., Blackard, W.G. Rubenstein, A.H. (1975) Proinsulin, insulin, and C-peptide concentrations in human portal and peripheral blood. Journal of Clinical Investigation, 55, 1278 1283.
36. Star, R.J.I. Rubenstein, A.H. (1974) Metabolism of endogenous proinsulin and insulin in man. Journal of Clinical Endocrinology and Metabolism, 38, 305 308.
37. Duckworth, W.C., Bennett, R.G. Hamel, F.G. (1998) Insulin degradation: progress and potential. Endocrine Reviews, 19, 608 624.
38. Zavaroni, I., Deferrari, G., Lugari, R., Bonora, E., Garibotto, G., Dall'Aglio, E., Robaudo, C. Gnudi, A. (1987) Renal metabolism of C-peptide in man. Journal of Clinical Endocrinology and Metabolism, 65, 494 498.
39. Dormandy, J.A., Charbonnel, B., Eckland, D.J., Erdmann, E., Massi-Benedetti, M., Moules, I.K., Skene, A.M., Tan, M.H., Lefebvre, P.J., Murray, G.D., Standl, E., Wilcox, R.G., Wilhelmsen, L., Betteridge, J., Birkeland, K., Golay, A., Heine, R.J., Koranyi, L., Laakso, M., Mokan, M., Norkus, A., Pirags, V., Podar, T., Scheen, A., Scherbaum, W., Schernthaner, G., Schmitz, O., Skrha, J., Smith, U. Taton, J. (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet, 366, 1279 1289.